Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 33B pseudogene 5 (ANKRD33BP5) is a non-coding genomic DNA element classified as a pseudogene, meaning it is a segment of DNA that resembles a functional gene but usually does not encode a functional protein[3][5]. Pseudogenes are often the result of gene duplication or retrotransposition but lose coding function through mutations. Some pseudogenes, especially those transcribed into RNA, may participate in regulatory roles, such as acting as competing endogenous RNAs (ceRNAs) that interact with microRNAs and influence the expression of other genes[6]. However, there is no evidence that ANKRD33BP5 encodes a functional protein or serves directly as a therapeutic target in any disease context. Most genomic databases list it as a pseudogene without established biological function, clinical significance, or direct pharmacological relevance[3][5][6]. Ankyrin repeat domain 33B pseudogene 5 is a non-coding pseudogene with no established protein product or direct therapeutic relevance; pseudogenes can participate in RNA regulatory networks but ANKRD33BP5 has no specific or validated biological or clinical function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 33B pseudogene 5 (ANKRD33BP5).